Research suggests that patients with high BMI levels may experience reduced efficacy of benralizumab due to systemic inflammation caused by elevated levels of obesity-related cytokines like TNF-α, IL-6, and leptin [66]. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.